Stay updated with breaking news from Outlayer Item. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A 55-year-old white man presented with the complaint of sudden onset central scotoma in both eyes for 1 month. The patient reported the condition slightly improved from the initial onset. His medical history was positive for syphilis, HIV, hyperlipidemia and anxiety. The patient reported that he was a former smoker, social drinker and used recreational drugs. His ocular history was unremarkable.
Few adolescents report speaking with their doctors about sexual health ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Other than conversations about puberty, less than one-thi...
Improving Compliance Through Sustained-release Delivery Systems for Glaucoma Management Exploring the Need for New Treatment Options in the Management of Glaucoma Sustained-release Delvery of Glaucoma Treatment: Comparing New and Emerging Options Glaucoma Drug Delivery Case Presentations Educational Tools Exploring the Need for New Treatment Options in the Management of Glaucoma Sustained-release Delvery of Glaucoma Treatment: Comparing New and Emerging Options Glaucoma Drug Delivery Case Presentations Educational Tools This activity is supported by an educational grant from Allergan, Inc. ...
A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting. Martin Reck, MD, PhD, head of thoracic oncology and head of the clinical trial department in the department of thoracic oncology at the Lung Clinic in
Moderna announced that it has requested an emergency use authorization from the FDA for its COVID-19 vaccine for use in adolescents aged 12 to 17 years. If authorized, it would become the second COVID-19 vaccine available for children in the United States after the Pfizer-BioNTech shot, which received an emergency use authorization (EUA) for children as young as age 12 years last month.